Examkin

Question

Difficulty: HardImmunologic and Inflammatory Processes

A 58-year-old man is evaluated in the intensive care unit for high fever, severe hypotension, and progressive respiratory distress. Four days ago, he received an infusion of CD19-directed chimeric antigen receptor (CAR) T cells for refractory diffuse large B-cell lymphoma. His temperature is 39.8°C (103.6°F), blood pressure is 82/50 mm Hg despite receiving 3 L of intravenous crystalloid over the past two hours, pulse is 128/min, and respirations are 28/min. Oxygen saturation is 88% on room air, which improves to 94% on a high-flow nasal cannula. Physical examination reveals warm extremities and bounding pulses. Laboratory studies demonstrate marked elevations in serum ferritin, C-reactive protein, and lactate. Blood cultures are drawn, and empiric broad-spectrum intravenous antibiotics are initiated. Despite these measures and the initiation of a norepinephrine infusion, the patient remains hemodynamically unstable. Which of the following best describes the primary molecular target of the most appropriate specific pharmacotherapy to reverse this patient's acute deterioration?

  1. Interleukin-6 receptorAnswer
  2. B
    Interleukin-1 receptor
  3. C
    Tumor necrosis factor-alpha
  4. D
    CD20 surface antigen
  5. E
    Calcineurin

Answer

The correct molecular target is the Interleukin-6 receptor.
The correct answer correctly identifies the Interleukin-6 (IL-6) receptor as the target of tocilizumab. This patient is presenting with severe Cytokine Release Syndrome (CRS), a predictable and potentially life-threatening complication of chimeric antigen receptor (CAR) T-cell therapy. When CAR-T cells bind to their target (e.g., CD19 on lymphoma cells), they undergo massive in vivo expansion and release cytokines such as interferon-gamma. This activates bystander immune cells, particularly host macrophages, which then secrete massive quantities of IL-6. IL-6 drives the classic CRS triad of high fever, capillary leak leading to hypoxia, and severe distributive shock. For severe CRS (defined by hypotension requiring vasopressors or significant hypoxia), the standard-of-care targeted therapy is tocilizumab, a monoclonal antibody directed against the IL-6 receptor, often given in conjunction with corticosteroids.

Step-by-Step Solution

1
Analyze the clinical presentation and recent interventions.
The patient developed distributive shock, fever, hypoxia, and significantly elevated inflammatory markers 4 days after receiving CD19-directed CAR-T cells.
Identifying the temporal relationship between CAR-T infusion and systemic inflammation establishes the primary differential diagnosis.
2
Formulate a diagnosis.
The clinical picture is classic for severe (Grade 3 or higher) Cytokine Release Syndrome (CRS).
CRS is a life-threatening complication of CAR-T therapy characterized by massive macrophage activation and profound cytokine elevation, predominantly IL-6.
3
Determine the specific pharmacologic intervention.
The patient requires tocilizumab (with or without corticosteroids) to reverse the hemodynamic instability.
While broad-spectrum antibiotics and vasopressors are essential supportive care, the specific antidote for severe CRS is IL-6 blockade.
4
Identify the molecular target of the chosen therapy.
Tocilizumab is a monoclonal antibody that competitively blocks the interleukin-6 (IL-6) receptor.
The question asks for the primary molecular target of the most appropriate specific pharmacotherapy.

Key Concept

Severe cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T-cell therapy is primarily driven by massive interleukin-6 (IL-6) production; the definitive targeted treatment is the IL-6 receptor antagonist tocilizumab.
Rate this question

Topics

Immunologic and Inflammatory Processes

More questions from this topic